McNairy, Margaret L. MD, MSc*,†; Howard, Andrea A. MD*,‡; El-Sadr, Wafaa M. MD, MPH, MPA*,‡
The demonstration of the efficacy of antiretroviral therapy (ART) in preventing HIV transmission offers promise for controlling the HIV epidemic.1–4 The HIV Prevention Trials Network (HPTN) 052 study demonstrated the efficacy of ART when used by HIV-infected persons for the prevention of HIV transmission in serodiscordant heterosexual couples.1 This clinical trial, in conjunction with a number of ecological, observational, and mathematical modeling studies, provides support for the concept of “Treatment as Prevention” (TasP). Other evidence from ecological and observational studies provides support for the potential role of ART for prevention of tuberculosis (TB).5,6 The potential for ART to prevent HIV transmission has resulted in advocacy for widespread implementation of TasP and has inspired discussions about a future AIDS-free generation.7 Mathematical modeling studies have also assessed the impact of TasP in conjunction with other prevention interventions on the HIV epidemic8 and its impact on the incidence of HIV-associated TB.9 In this article, we present the evidence regarding the use of ART for prevention of both HIV and TB and summarize key issues that need to be addressed to appropriately situate this intervention within the context of other available prevention interventions. We also highlight the need for further research to provide empiric data on the effect of ART for individual health and its effects on the trajectory of the HIV and TB epidemics at population level.
EFFECT OF ART ON HIV INCIDENCE
The HPTN 052 study was a randomized-controlled trial that compared early versus delayed initiation of ART in 1763 serodiscordant heterosexual couples in 9 countries.1 HIV-infected partners with CD4+ counts between 350 and 550 cells/μL were randomized to receive early therapy (ie, immediate ART) or delayed therapy at CD4+ count of 200–250 cells/μL or onset of HIV-related symptoms. A total of 39 HIV-1 transmissions were observed, of which 28 were virologically linked to the infected partner. Of the linked transmissions, only 1 occurred in the early therapy group (hazard ratio [HR]: 0.04, 95% confidence interval [CI]: 0.01 to 0.27) with evidence of 96% protection. In terms of overall transmission, ART had a protective effect of 89%.
There have been a series of ecological, observational, and mathematical modeling studies supporting TasP. Ecological studies from San Francisco, South Africa, Taiwan, and Canada suggested that expansion of ART use was associated with a reduction in the number of new HIV infections or expected HIV cases.10–14 In the study from San Francisco, an association between expansion of ART use and decreases in community viral load was reported, measured as the sum of the most recent viral loads in HIV-infected individuals, over the period between 2004 and 2008 in conjunction with a decrease in number of new infections.11 Data from the British Columbia, Canada, revealed a significant inverse association between the number of individuals on ART and the number of individuals newly testing HIV positive per year.12 Similarly, a recent study from South Africa demonstrated that increase in coverage of ART use in 1 region was associated with a decrease in HIV incidence.14 In the latter study, an HIV-uninfected individual living in a community with high ART coverage, defined as 30%–40% of persons with HIV infection on ART, was 38% less likely to acquire HIV than an individual living in a community with ART coverage of less than 10%.
Observational studies supporting an association between ART use and decrease in HIV transmissibility have largely been derived from studies that included HIV serodiscordant couples. The earliest study reporting such an association was with use of zidovudine monotherapy,15 followed by further studies that included the use of combination ART in HIV-discordant couples.16–20 Only 1 study failed to demonstrate association between use of ART and decrease in transmission, the latter including a limited number of discordant couples from China.21 A 2011 review of 7 observational studies and 1 randomized-controlled trial collectively identified 464 episodes of HIV transmission among serodiscordant couples, of which 72 episodes occurred among couples in which the HIV-infected partner was on ART and 392 occurred in couples in the absence of ART.22 The rate ratio of HIV transmission for these studies was 0.34 (95% CI: 0.13 to 0.92)—ie, there was an estimated 66% decrease in risk of HIV transmission with ART use by the HIV-infected partner.
In a more recent study from China, the effect of ART on HIV transmission among 38,862 heterosexual serodiscordant couples was reported from national HIV epidemiology and treatment databases between 2003 and 2011.19 A total of 1,613 HIV transmissions were identified, with an overall transmission rate of 1.6/100 person-years (95% CI: 1.5 to 1.7). The rate of transmission for the treated couples was 1.3/100 person-years (95% CI: 1.2 to 1.3), which was significantly lower than the rate in the ART-naive cohort (2.6/100 person-years [95% CI: 2.4 to 2.8]; adjusted HR: 0.74 [95% CI: 0.65 to 0.84]). This study’s findings are particularly important as they demonstrate the efficacy of this intervention outside of the context of a research study. A key limitation of both the ecological and observational studies is that they cannot support causal association between use of ART and decrease in HIV infections, as the latter effect may have been caused by other factors.
Evidence supporting ART for prevention is also derived from mathematical modeling studies. In a study by Granich et al,23 which was based on optimistic assumptions of ART coverage and adherence and used data from the South African epidemic, expansion of use of ART for all individuals identified with HIV infection was shown to have the potential to lead to HIV elimination, defined as HIV incidence less than 0.1%, in 50 years. A meta-analysis of 12 modeling studies regarding the HIV epidemic in South Africa found that TasP could substantially reduce new infections under similarly optimistic assumptions of annual voluntary testing, followed by greater than 90% linkage to care with immediate ART initiation and 85% of patients remaining on treatment over 3 years.24 The HIV Modeling Consortium raised several priority issues for future modeling studies of ART for prevention including the need to report on the impact of decisions over both the short and long term, to estimate the impact of current programs rather than radically different future programs, and to use real-life assumptions about testing, linkage to and retention in care, and medication adherence.25–27 The authors also encouraged future models to examine negative outcomes of expanded treatment programs, including their potential influence on risk behaviors by individuals living with HIV.
EFFECT OF ART ON TB INCIDENCE
HIV-infected individuals have 20–37 times the risk of developing TB compared with HIV-uninfected individuals.28 The case-fatality rates among HIV-infected persons are several-fold higher than those without HIV infection and are strongly associated with the degree of immunodeficiency.29,30 Data from clinical trials and observational studies have shown that initiation of ART in patients with TB is associated with a reduction in mortality.31–34 In addition, data from clinical trials, cohort studies, ecological studies, and mathematical modeling suggest that use of ART has the potential to reduce the risk of TB in patients with HIV infection.1,35–41
A recent meta-analysis of 3 randomized-controlled trials and 8 cohort studies from resource-limited countries that compared TB incidence by ART use in HIV-infected adults demonstrated that ART was strongly associated with a reduction in TB incidence (HR: 0.35, 95% CI: 0.28 to 0.44).5 This association was significant across all baseline CD4+ count strata: less than 200 cells/µL (HR: 0.16, 95% CI: 0.07 to 0.36), 200–350 cells/µL (HR: 0.34, 95% CI: 0.19 to 0.60), and greater than 350 cells/µL (HR: 0.43, 95% CI: 0.30 to 0.63), without evidence of HR modification with respect to baseline CD4+ count. Clinical trial data demonstrated nearly identical reductions in TB incidence when initiating ART at CD4+ count 200–350 cells/µL (HR: 0.50, 95% CI: 0.28 to 0.83) compared with <200 cells/μL42 and at greater than 350 cells/µL (incidence rate ratio: 0.51, 95% CI: 0.28 to 0.91) when compared with CD4+ count of 200–250 cells/μL.1 A reduction in TB incidence was also demonstrated in high-income countries following ART initiation in adults with CD4+ counts greater than 350 cells/µL.6 However, it is important to note that the absolute reduction in TB rates is greatest at lower CD4+ strata, and no evidence is available for the effect of use of ART at CD4+ count >500 cells/μL on the incidence of TB. Surprisingly, findings from HPTN 052 did not show a decrease in pulmonary TB incidence in individuals who initiated ART at CD4+ count between 350 and 550 cells/μL versus those who initiated ART at CD4+ 200–250 cells/μL, whereas there were fewer episodes of extrapulmonary TB, largely presumptive in nature, with early use of ART.1 Of note, a trial conducted in Botswana found that reductions in TB incidence with ART use at CD4+ counts <200 cells/µl were similar among HIV-infected adults receiving 6 months of isoniazid preventive therapy (IPT) with either positive or negative tuberculin skin tests,38 suggesting that ART impacts risk of TB following either endogenous reactivation or exogenous exposure.43
Studies evaluating the impact of ART on TB incidence at a population level are more limited. An ecological study from a high HIV and TB burden community of approximately 15,000 persons in South Africa demonstrated an association between implementation of an ART program using criteria based on prevailing national guidelines and TB notification rates. Between 2002 and 2008, as ART coverage increased from 0% to 21% of the HIV-infected population, adult TB notification rates increased to a maximum of 2,500 cases per 100,000 population between 2002 and 2005, then decreased by an average of 202 cases/100,000/yr, reaching 2,000 cases per 100,000 population in 2008.44 Notably, the decline in new TB notifications was observed exclusively among the HIV-infected population receiving ART. Furthermore, 2 cross-sectional surveys performed in the same community showed a significant reduction in TB prevalence among a randomly selected HIV-infected population sample, from 9.2% in 2005 to 3.6% in 2008 (adjusted P = 0.013), whereas the prevalence among HIV-negative individuals remained unchanged.45 Similar findings were reported in a retrospective descriptive study in which ART scale-up between 2005 and 2009 in a rural district in Malawi was associated with a 33% (95% CI: 27 to 39%) reduction in new TB cases and a 25% (95% CI: 9 to 49%) reduction in recurrent cases.39 It is also important to note that, in these 2 studies, ART was initiated at advanced stages of HIV disease, largely at CD4+ count of <200 cells/μL. Given the observational nature of these studies, they are unable to demonstrate a causal relationship between use of ART and reduction in TB incidence/prevalence. The observed trends may have been confounded by high mortality before case diagnosis, provision of IPT (in Malawi), or changes in TB case detection efficiency. It is likely that TB case finding was increased in the ART programs, which may have led to a reduction in TB transmission because of undiagnosed, untreated TB.
Mathematical modeling using data from 9 countries in sub-Saharan Africa suggested that widespread implementation of annual HIV testing and ART initiation early in the course of HIV infection regardless of CD4+ count would lead to rapid reduction in HIV-associated TB at the population level.41 Assuming that coverage increases to 95% by 2015, initiating ART within 5 years of HIV seroconversion would reduce the incidence of HIV-related TB in 2015 by 48% (range: 37%–55%).41 The reduction would be greater if ART is started within 2 years of HIV seroconversion (63%; range: 52%–72%). More substantial reductions would be anticipated if the intervention is sustained until 2050: if ART is started 5 or 2 years after HIV seroconversion, the incidence in 2050 will be reduced by 66% (range: 57%–80%) and 95% (range: 93%–96%), respectively.
TasP: WHO SHOULD BE PRIORITIZED?
Much of the ongoing discussion regarding TasP has centered on initiation of ART for individuals with higher CD4+ count who would otherwise not be eligible for ART for their own health. Expansion of ART to individuals with higher CD4+ counts has been noted to be associated with certain challenges. Studies have shown that HIV-infected individuals with higher CD4+ counts are at higher risk for loss to follow-up both during the pre-ART phase and when they receive ART.46 In addition, there remains uncertainty with regard to the balance of benefits versus risks of ART for the health of HIV-infected individuals at higher CD4+ counts.47,48
It is also ironic that, although substantial attention has been given to initiation of ART at a higher CD4+ count, largely for the purpose of prevention of HIV transmission, there remains a gap in coverage for individuals who are in urgent need of ART for their own health and where use of ART will also have substantial prevention effects.49 In most resource-rich and resource-limited countries, ART initiation is occurring at advanced stages of HIV disease, significantly below the recommended CD4+ count thresholds.42,50,51 A recent study of 36,411 adult patients who started ART between 2005 and 2009 in Mozambique reported that the proportion of patients with late ART initiation, defined as initiation at a CD4+ count < 100 cells/µL or WHO clinical stage IV, decreased from 46% to 27% during 2005–2007 but remained constant at more than 33% during the period between 2007 and 2009.50 Globally, it is estimated that only 47% (range: 44%–50%) of adults and children in low- and middle-income countries who were eligible for ART for their own health have access to such treatment.52 Thus, there is a huge need for the expansion of ART access to those who need ART for their own health (at CD4+ count < 350 cells/µL) and for prevention of transmission to others, the latter a benefit of treatment not appreciated in this population. Importantly, data from 1 discordant couples study demonstrated that the risk of HIV transmission follows a gradient with HIV-infected individuals with lower CD4+ counts at higher risk of transmission to their sexual partner.16 Indeed, it is important to note that the weight of evidence in support of TasP from ecological and observational studies is based largely on the effect of ART initiation at lower CD4+ counts, ie, when the HIV-infected partner was eligible for ART based on their own health needs, as indicated earlier (Table 1).10–14,17–19,53 In only 2 discordant couples studies, an observational study and HPTN 052, was ART initiated in HIV-infected individuals for the purpose of HIV prevention, ie, when the HIV-infected partners were not yet eligible for ART for their own health.1,16 Similarly, the evidence in support of the effect of ART use on HIV incidence is derived from use of ART in HIV-infected individuals with low CD4+ count.
TABLE 1-a Summary of...Image Tools
Thus, expansion of treatment for those who need it for their own health is likely to have substantial benefit for them in terms of prevention of HIV and TB-related morbidity and mortality and decreased HIV incidence among their HIV-uninfected partners and potentially protecting their families, households, and communities from risk of TB. Clearly, expansion of TasP to those at earlier stages of HIV disease is an important frontier for further research and implementation.
TABLE 1-b Summary of...Image Tools
TasP: AN UNLIKELY PANACEA
Enthusiasm for TasP must be tempered by acknowledging that it is not a panacea but rather its success is dependent on a multiplicity of other complementary and necessary interventions.54 Behavioral, biomedical, and structural interventions are required to ensure that various components of the HIV care cascade are optimized to achieve the ultimate goal of TasP. Achieving higher coverage with ART for those in need will require expansion of HIV testing, using innovative approaches such as provider-initiated testing and counseling, household testing, and community-focused approaches.55,56 It will also require attention to maximize every step of the HIV care cascade from linkage of those found to be HIV positive to retention in care, prompt determination of ART eligibility, and initiation of ART with provision of adherence support.54 Without attention to the HIV care cascade, the promise of TasP as an intervention for both HIV treatment and HIV prevention will fail to be realized57 (Figure 1). Two meta-analyses from sub-Saharan Africa demonstrated that less than a third of persons testing HIV positive remain in care until ART initiation.58,59 Results are similar in the United States, where 19%–29% of persons with HIV infection are estimated to achieve viral load suppression.60–62
In reality, it may be difficult to achieve the magnitude of coverage with ART for all individuals with HIV in a community as presumed in many of the modeling studies, supporting the need for other HIV and TB prevention interventions. As noted in Figure 1, HIV testing is the foundation of all prevention interventions. Although, for those individuals found to be HIV infected, TasP is an important prevention intervention when combined with supportive interventions, those found to be HIV-uninfected should also be candidates for HIV prevention interventions. They need to be linked to appropriate prevention interventions such as voluntary medical male circumcision (VMMC) and preexposure prophylaxis (PrEP), with ongoing counseling and adherence support, as needed, and repeat HIV testing. Despite substantial evidence in support of the efficacy of VMMC for prevention of HIV transmission,63–65 its implementation and scale-up has been suboptimal in some settings.66 Availability of new nonoperative methods for male circumcision that do not require anesthesia and can be performed by nurses holds great promise.67,68 A recent study demonstrated that expansion of VMMC is cost effective and may have a substantial effect on decreasing the number of new HIV infections in the short term, with TasP demonstrating substantial effect in the long term.8 PrEP using antiretroviral drugs in HIV-uninfected individuals is also a promising intervention shown to be efficacious in several studies,2,4 whereas conflicting results have been noted in other studies where adherence with PrEP was compromised.69,70 That a significant proportion of transmissions in couples in HPTN 052 and other discordant couple studies were unlinked highlights the potential importance of PrEP if monogamy among couples is not assured. PrEP may also be appropriate for individuals at high risk who are unaware of their partner’s HIV status or in settings where an HIV-infected partner is unwilling or unable to take ART for prevention.
Enthusiasm for the potential effect of ART on TB incidence should not divert resources from other TB control strategies, including the “three I’s,” ie, intensified case finding, IPT, and infection control, in addition assuring provision of directly observed therapy for those diagnosed with TB.71,72 A comprehensive public health approach that includes these strategies is needed to control the TB epidemic, particularly among HIV-infected individuals. HIV-infected individuals on ART remain at an increased risk for TB when compared with HIV-uninfected individuals, even when their CD4+ counts are high.73,74 With the increase in survival associated with ART, the lifetime risk of TB in HIV-infected persons in the absence of other interventions is likely to remain high. IPT and ART prevent TB via complementary mechanisms,75 and evidence supports an additive protective benefit from concomitant IPT use among individuals on ART.36,37 To provide IPT safely, it must be implemented in the context of intensified case finding, to prevent the development of drug resistance from inadvertently prescribing monotherapy to individuals with undiagnosed TB. Implementation of infection control measures is also essential to prevent nosocomial transmission of TB in health care settings where ART is provided.
There is an urgent need for empiric data to evaluate the effectiveness of TasP at a population level. Two studies are planned to address this question, the HPTN 071 (PopART) Study in South Africa and Zambia and the Mochudi Study in Botswana.76 In addition, there is a paucity of data regarding whether ART use will be an efficacious intervention for prevention of HIV transmission in key populations, particularly among men who have sex with men and injection drug users.49
There is also an urgent need to obtain empiric data to assess the potential benefits and risks associated with use of ART for individuals at higher CD4+ counts, who are largely the target group of current considerations for TasP.77 Few data exist with regard to this issue in patients with CD4+ count >350 cell/μL from resource-limited settings, supporting the need for clinical trials to inform this question.47 The ongoing START study is aiming to address this question largely in developed countries,78 whereas the TEMPRANO study in Cote d’Ivoire (ANRS12136) may provide some insights on this question. However, neither study will provide definitive answers to the question of the benefits and risks of early versus deferred ART in terms of key outcomes including mortality, TB incidence, and hospitalizations in resource-limited countries.47
There is the need for implementation research that aims at examining the “how” with regard to implementation of TasP and its scale-up, if found to be effective at population level.
Expanded use of ART holds great promise for saving lives and enhancing the health and well being of persons living with HIV and for the prevention of HIV and TB. The evidence for TasP should serve to further energize efforts to reach all those who need ART for their own health as an important priority. Aspiration for TasP should not distract attention from the quality of HIV programming, the effectiveness of the HIV care cascade, and the need for inclusion of other HIV prevention interventions and other TB prevention measures. Important questions that remain to be answered include which population to prioritize, what other interventions to use, how to integrate TasP in the health system, how best to use ART for the benefit of individuals and society, and how to measure its effectiveness and impact at population level.
1. Cohen MS, Chen YQ, McCauley M, et al.. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
2. Grant RM, Lama JR, Anderson PL, et al.. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–2599.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al.. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–434.
4. Baeten JM, Donnell D, Ndase P, et al.. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.
5. Suthar AB, Lawn SD, del Amo J, et al.. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9:.
6. HIV Causal Collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis. 2012;54:1364–1372.
7. Cohen MS, Holmes C, Padian N, et al.. HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response. Health Aff (Millwood). 2012;31:1439–1449.
8. Barnighausen T, Bloom DE, Humair S. Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proc Natl Acad Sci USA. 2012;109:21271–21276.
9. Lawn SD, Harries AD, Williams BG, et al.. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis. 2011;15:571–581.
10. Porco TC, Martin JN, Page-Shafer KA, et al.. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004;18:81–88.
11. Das M, Chu PL, Santos GM, et al.. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5:.
12. Montaner JS, Lima VD, Barrios R, et al.. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532–539.
13. Fang CT, Hsu HM, Twu SJ, et al.. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis. 2004;190:879–885.
14. Tanser F, Barnighausen T, Grapsa E, et al.. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339:966–971.
15. Musicco M, Lazzarin A, Nicolosi A, et al.. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med. 1994;154:1971–1976.
16. Donnell D, Baeten JM, Kiarie J, et al.. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092–2098.
17. Del Romero J, Castilla J, Hernando V, et al.. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ. 2010;340:.
18. Melo MG, Santos BR, De Cassia Lira R, et al.. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. Sex Transm Dis. 2008;35:912–915.
19. Jia Z, Ruan Y, Li Q, et al.. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet. 2012. doi: 10.1016/S0140-6736(12)61898-4.
20. Sullivan P, Kayitenkore K, Chomba E, et al.. Reduction of HIV transmission risk and high risk sex while prescribing ART: results form discordant couples in Rwanda and Zambia. Abstract 52bLB. Paper presented at: Conference on Retrroviruses and Opportunistic Infections; 2009; Montreal, Canada.
21. Lu W, Zeng G, Luo J, et al.. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr. 2010;55:232–238.
22. Anglemyer A, Rutherford G, Egger M, et al.. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database System Rev. 2011;5:.
23. Granich RM, Gilks CF, Dye C, et al.. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57.
24. Eaton JW, Johnson LF, Salomon JA, et al.. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9:.
25. Meyer-Rath G, Over M. HIV treatment as prevention: modelling the cost of antiretroviral treatment—state of the art and future directions. PLoS Med. 2012;9:.
26. Barnighausen T, Salomon JA, Sangrujee N. HIV treatment as prevention: issues in economic evaluation. PLoS Med. 2012;9:.
27. HIV Modeling Group Consortium. HIV treatment as prevention: models, data, and questions—towards evidence-based decision-making. PLoS Med. 2012;9:.
28. World Health Organization. Global Tuberculosis Control 2009: Epidemiology, Strategy, and Financing. Geneva: WHO; 2009.
29. Ackah AN, Coulibaly D, Digbeu H, et al.. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d’Ivoire. Lancet. 1995;345:607–610.
30. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15:143–152.
31. Abdool Karim SS, Naidoo K, Grobler A, et al.. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697–706.
32. Manosuthi W, Chottanapand S, Thongyen S, et al.. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43:42–46.
33. Velasco M, Castilla V, Sanz J, et al.. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr. 2009;50:148–152.
34. Sanguanwongse N, Cain KP, Suriya P, et al.. Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defic Syndr. 2008;48:181–189.
35. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059–2064.
36. Golub JE, Pronyk P, Mohapi L, et al.. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631–636.
37. Golub JE, Saraceni V, Cavalcante SC, et al.. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441–1448.
38. Samandari T, Agizew TB, Nyirenda S, et al.. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:1588–1598.
39. Zachariah R, Bemelmans M, Akesson A, et al.. Reduced tuberculosis case notification associated with scaling up antiretroviral treatment in rural Malawi. Int J Tuberc Lung Dis. 2011;15:933–937.
40. Middelkoop K, Bekker LG, Myer L, et al.. Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community. J Acquir Immune Defic Syndr. 2011;56:263–269.
41. Williams BG, Granich R, De Cock KM, et al.. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci USA. 2010;107:19485–19489.
42. Severe P, Juste MA, Ambroise A, et al.. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257–265.
43. Wood R, Lawn SD. Antiretroviral treatment as prevention: impact of the ‘test and treat' strategy on the tuberculosis epidemic. Curr HIV Res. 2011;9:383–392.
44. Middelkoop K, Wood R, Bekker LG. The impact of antiretroviral treatment programs on tuberculosis notification rates. Int J Tuberc Lung Dis. 2011;15:; author’s reply 1714–1715.
45. Middelkoop K, Bekker LG, Myer L, et al.. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med. 2010;182:1080.
46. Teasdale C, Mugisha V, Wang C, et al.. Determinants of mortality and loss to follow-up among adult patients in pre-ART care and on ART in Rwanda. Abstract number Y-132. Paper presented at: Conference of Retroviruses and Opportunistic Infections; 2013; Atlanta, GA.
47. De Cock KM, El-Sadr WM. When to start ART in Africa—an urgent research priority. N Engl J Med. 2013;368:886–889.
48. Sabin C, Cooper D, Collins S, et al.. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons. AIDS. 2013. doi: 10.1097/QAD.0b013e328360d546.
49. Cohen MS, Muessig KE, Smith MK, et al.. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS. 2012;26:1585–1598.
50. Lahuerta M, Lima J, Nuwagaba-Biribonwoha H, et al.. Factors associated with late antiretroviral therapy initiation among adults in Mozambique. PLoS One. 2012;7:.
51. Lahuerta M, Ue F, Hoffman S, et al.. The problem of late ART initiation in sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved. 2013;24:359–383.
52. WHO, UNAIDS, USAID. Global HIV/AIDS Response, Epidemic Update and Health Sector Progress Torwards Universal Access-Progress Report 2011. Geneva: WHO; 2011.
53. Katz MH, Schwarcz SK, Kellogg TA, et al.. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health. 2002;92:388–394.
54. McNairy ML, Cohen M, El-Sadr WM. Antiretroviral therapy for prevention is a combination strategy. Curr HIV/AIDS Rep. 2013. doi: 10.1007/s11904-013-0152-1.
55. Were W, Mermin J, Bunnell R, et al.. Home-based model for HIV voluntary counselling and testing. Lancet. 2003;361:.
56. Lugada E, Millar D, Haskew J, et al.. Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya. PLoS One. 2010;5:.
57. McNairy ML, El-Sadr WM. The HIV care continuum: no partial credit given. AIDS. 2012;26:1735–1738.
58. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8:.
59. Mugglin C, Estill J, Wandeler G, et al.. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2012. doi: 10.1111/j.1365-3156.2012.03089.x.
60. Vital signs: HIV prevention through care and treatment—United States. MMWR Morb Mortal Wkly Rep. 2011;60:1618–1623.
61. Gardner EM, McLees MP, Steiner JF, et al.. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793–800.
62. Marks G, Gardner LI, Craw J, et al.. The spectrum of engagement in HIV care: do more than 19% of HIV-infected persons in the US have undetectable viral load? Clin Infect Dis. 2011;53:1168–1169; author’s reply 1169–1170.
63. Bailey RC, Moses S, Parker CB, et al.. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643–656.
64. Auvert B, Taljaard D, Lagarde E, et al.. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:.
65. Gray RH, Kigozi G, Serwadda D, et al.. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657–666.
66. World Health Organization. Joint Strategic Action Framework to Accelerate the Scale-up of Voluntary Medical Male Circumcision for HIV Prevention in Eastern and Southern Africa. Geneva: WHO; 2011.
67. Mutabazi V, Kaplan SA, Rwamasirabo E, et al.. One arm, open label, prospective, cohort field study to assess the safety and efficacy of the PrePex device for scale up of non-surgical circumcision when performed by nurses in resource limited settings for HIV prevention. J Acquir Immune Defic Syndr. 2013 [Epub ahead of print].
68. Bitega JP, Ngeruka ML, Hategekimana T, et al.. Safety and efficacy of the PrePex device for rapid scale-up of male circumcision for HIV prevention in resource-limited settings. J Acquir Immune Defic Syndr. 2011;58:e127–e134.
69. Marrazzo J, Ramjee G, Nair G, et al..; and the VOICE Study Team. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003), Abstract 26LB. Paper presented at; Conference on Retroviruses and Opportunistic Infections; 2013; Atlana, GA.
70. Van Damme L, Corneli A, Ahmed K, et al.. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–422.
71. World Health Organization. Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living With HIV in Resource-Constrained Settings. Geneva: WHO; 2011.
73. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet. 2006;368:1254–1259.
74. Sonnenberg P, Glynn JR, Fielding K, et al.. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005;191:150–158.
75. Lawn SD, Wood R, De Cock KM, et al.. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis. 2010;10:489–498.
76. HIV Prevention Trials Network. 2013. Available at: http://www.hptn.org/
. Accessed March 22, 2013.
77. De Cock KM, El-Sadr WM, Ghebreyesus TA. Game changers: why did the scale-up of HIV treatment work despite weak health systems? J Acquir Immune Defic Syndr. 2011;57(suppl 2):S61–S63.
78. Babiker AG, Emery S, Fatkenheuer G, et al.. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials. Apr 30 2012.
79. Health SADo. National Antiretroviral Treatment Guidelines. Pretoria, South Africa: South African National Department of Health; 2010.
80. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Department of Health and Human Services; 1998–2012. Washington, DC: Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/guidelines/archive/adult-and-adolescent-guidelines/
81. Carpenter CC, Cooper DA, Fischl MA, et al.. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA.
Jan 19 2000;283(3):381–390.
82. Report of the NIH panel to define principles of therapy of HIV infection. Ann Intern Med. 1998;128(12 Pt 2):1057–1078.
83. Carpenter CC, Fischl MA, Hammer SM, et al.. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78–86.
84. Carpenter CC, Fischl MA, Hammer SM, et al.. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962–1969.
85. Carpenter CC, Fischl MA, Hammer SM, et al.. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996;276:146–154.
86. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva: WHO; 2006.
© 2013 Lippincott Williams & Wilkins, Inc.